Parenteral erythromycin for potential use to empty retained gastric contents encountered during upper gastrointestinal endoscopic procedures

Nahel Saied¹, Ashish Chopra², Banke Agarwal²#

¹Department of Anesthesia, Saint Louis University School of Medicine, St. Louis, USA
²Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, USA
Email: #agarwalb@slu.edu

Received 14 June 2012; revised 18 July 2012; accepted 29 July 2012

ABSTRACT

Background: Erythromycin, a prokinetic agent facilitates gastric emptying. We report our experience with the use of IV erythromycin for emptying retained gastric contents encountered during elective upper gastrointestinal endoscopy (UGIE) procedures in an effort to complete of the procedure on the same day. Patients and methods: This retrospective case series includes 15 patients who were found to have a significant amount of retained gastric contents while undergoing an UGIE procedure. After aborting the procedure, a repeat endoscopic examination was performed 30 - 120 minutes following administration of 250 - 500 mg erythromycin intravenously. Results: During repeat endoscopy, ten patients had complete emptying of the gastric contents, three patients had partial emptying and in two patients the amount of residual contents was largely unchanged. Both these patients were later found to have high grade mechanical gastric outlet obstruction. No anesthesia or procedure related complications were noted. Conclusion: Parenteral erythromycin can rapidly empty retained gastric contents encountered during UGIE procedures in a significant proportion of patients. Erythromycin can potentially be tried for safe completion of procedure on the same day.

Keywords: Erythromycin; Endoscopy; Gastric Contents

1. INTRODUCTION

Peri-operative pulmonary aspiration (PPA) is a dreaded complication in patients who undergo anesthesia, especially so in patients requiring emergent surgery or those with delayed gastric emptying [1,2]. Despite adequate pre-procedure fasting, retained food in stomach is not frequently encountered during endoscopy and usually leads to aborting the procedure. Procedure cancellation and postponement can sometimes lead to inordinate treatment delay or inconvenience to the patients and their families. The ability to rapidly empty gastric contents in these patients could potentially allow the performance of the procedure later on the same day and minimize the problems due to cancellation and rescheduling.

Gastric pro-kinetic agents including erythromycin are often used prior to sedation to facilitate gastric emptying in certain high risk patients [3]. However, the supporting data for this use is indirect and largely based on patients with an average risk for PPA [4,5]. In this case series, we report our experience with intravenous erythromycin for emptying gastric content retained despite overnight fasting, in patients who were scheduled to undergoing an elective upper gastrointestinal endoscopic procedure.

2. PATIENTS AND METHODS

This is a retrospective study involving patients who underwent upper gastrointestinal endoscopic (UGIE) procedures in our endoscopy unit after January 2004. After obtaining approval from the institutional review board of the Saint Louis University School of Medicine, the medical records of patients who had received intravenous erythromycin in an effort to empty retained gastric contents during UGIE procedure were reviewed. Careful attention was paid to the medical conditions and the medications that are known to be associated with delayed gastric emptying. In addition, endoscopic findings before and after the administration of intravenous erythromycin, time to repeat endoscopic examination, and dose of erythromycin used were recorded.

All patients scheduled for UGIE in our unit are advised to fast overnight (minimum of 6 hours). The fasting interval was confirmed by an endoscopy nurse and an anesthesiologist independently at the time of registration and again during pre-procedure evaluation. A detailed

*There was no funding support for this manuscript. None of the authors have any potential conflict of interest relevant to this manuscript.

#Corresponding author.
medical history including a list of medications was taken by a physician’s assistant or a nurse practitioner at the time of scheduling the procedure and again by the anesthesiologists during pre-anesthesia evaluation.

During endoscopy, if we encountered significant amount of residual gastric contents (solid food) that could potentially interfere with adequate examination and increase the risk of aspiration, we immediately withdrew the endoscope and terminated the procedure. Patients then received Erythromycin (250 or 500 mg) intravenously in the patients’ holding area and were brought back to the procedure room 30 - 120 minutes after the infusion was completed depending upon the availability of the procedure room. Under conscious sedation, the stomach was then re-examined with a forward viewing endoscope for residual gastric contents prior to proceeding with the remaining part of the procedure. Inpatients who failed to empty the gastric contents after IV erythromycin, the procedure was aborted and the patients were brought back for endoscopy after 48 hours of clear liquid diet followed by 12 hour fasting. This approach of using IV erythromycin instead of canceling the procedure was deemed necessary because of the relative urgency of the procedure.

3. RESULTS

Table 1 summarizes the characteristics, including list of co-morbid conditions and medications, of 15 patients included in this study. The mean age of 15 patients (7 female) was 59.3 ± 16.2 years. The dose of intravenous erythromycin used was 250 - 500 mg. The mean time from the end of erythromycin infusion and repeat endoscopy was 58.7 ± 22.1 minutes (range 30 - 120 minutes). During repeat endoscopy, complete emptying of the gastric contents was noted in 10 patients (Figure 1), three patients had partial emptying (less than 30% of gastric contents remaining) and in two patients, the amount of residual contents was largely unchanged from prior examination. No anesthesia or procedure related complication occurred in these patients.

The co-morbid medical conditions or medications that are known to significantly delay gastric emptying, which were found in our study patients are marked in italics in Table 1. All but one patient in our study who had retained food in the stomach at the time of endoscopy had one or more of these predisposing factors. The most common predisposing medical conditions were diabetes mellitus (n = 7), hypothyroidism (n = 3) and parkinsonism (n = 1). The medications with significant effects on gastric emptying included narcotic analgesics (propoxyphene, oxycodone, hydrocodone), antidepressants (amitriptyline, fluoxetine, duloxetine, gabapentin, vanlafaxine) and calcium channel blockers (diltiazem). Three patients with partial emptying after IV erythromycin had multiple medications and medical conditions associated with delayed gastric emptying. The two patients in whom erythromycin completely failed to empty the stomach contents were subsequently found to have a high-grade gastric outlet obstruction; one patient had duodenal compression by pancreatic cancer and the other patient had a large pancreatic pseudocyst pressing and deforming the gastric antrum and pylorus. The presence of high grade mechanical obstruction in these patients was found only at the time of repeat endoscopy performed later.

4. DISCUSSION

Erythromycin is a motilin-receptor agonist, with strong gastric prokinetic properties and is used in patients with gastroparesis to relieve symptoms [6], to facilitate early nutritional intake in critically injured trauma victims [7] and improves endoscopic visualization in patients with acute upper gastrointestinal bleeding [8,9]. Erythromycin is also recommended to empty the stomach prior to anesthesia in certain high risk patients, though there is limited supporting data. When administered three hours prior to anesthesia in unselected patients without an increased risk for PPA, erythromycin decreased the volume of gastric contents and their acidity [10]. In one pediatric patient, parental erythromycin was used successfully to facilitate gastric emptying prior to emergency anesthesia [11].

Using radionuclide scintigraphy, intravenous erythromycin was found to dramatically accelerate emptying of both solids and liquids with 50% and 100% gastric emptying observed at 10 minutes and 60 minutes in healthy volunteers and at 20 minutes and 150 minutes in diabetics with gastroparesis [6]. In our cohort of patients with retained food despite adequate pre-operative fasting, we observed complete gastric emptying within 30 - 120 minutes after erythromycin infusion in ten patients. In three patients, the gastric emptying was partial (about 70%) at repeat endoscopy. It is possible that these three patients would have emptied the remaining food had we waited longer before the repeat endoscopy. Unfortunately, that cannot be determined from our data. The patients with partial emptying had multiple medical conditions or medications which slow gastric emptying potentially making these patients much more resistant to erythromycin.

Erythromycin is well tolerated, with minimal risk of allergic reactions and does not have significant interactions with most anesthetic agents. It did not cause any problems in the two patients with high grade mechanical obstruction with large amount of retained food. We encountered no complications related to erythromycin, anesthesia, or aspiration pneumonia in our cohort. Therefore, a trial of IV erythromycin with a cautiously performed endoscopy under light sedation may be reasonable in patients who are found to have retained food in the stomach during urgent or emergent UGIE procedures.
Table 1. The demographics, list of co-morbid conditions, medications, diagnosis, IV erythromycin dose and outcome of the 15 patients included in this case series. Co-morbid conditions and medications known to be associated with delayed gastric emptying are marked in *italics*.

<table>
<thead>
<tr>
<th>Pt #</th>
<th>Age</th>
<th>sex</th>
<th>PMH</th>
<th>Medications</th>
<th>Indication for endoscopy</th>
<th>Diagnosis</th>
<th>IV-ER dose</th>
<th>Time after IV-ER</th>
<th>Gastric emptying</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>73</td>
<td>M</td>
<td><em>Diabetes</em>, HTN, GERD, chronic pancreatitis</td>
<td>Glyburide, lisinopril, pantoprazole, propoxyphene, pancreatic enzymes</td>
<td>Pancreatic mass</td>
<td>Pancreatic adenocarcinoma</td>
<td>500 mg</td>
<td>60</td>
<td>Complete</td>
</tr>
<tr>
<td>2</td>
<td>49</td>
<td>F</td>
<td>Hepatitis C cirrhosis, subdural hematoma, <em>diabetes</em>, s/p cholecystectomy</td>
<td>Spironolactone, naproxen, docusate, aspirin, insulin</td>
<td>Submucosal gastric mass</td>
<td>Gastrointestinal stromal tumor</td>
<td>250 mg</td>
<td>120</td>
<td>Complete</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>M</td>
<td>Chronic pancreatitis, s/p appendicectomy</td>
<td>Oxycodone, amitryptilline, carisoprodol</td>
<td>Recurrent acute pancreatitis</td>
<td>Chronic pancreatitis</td>
<td>250 mg</td>
<td>75</td>
<td>Complete</td>
</tr>
<tr>
<td>4</td>
<td>47</td>
<td>F</td>
<td>s/p radical mastectomy for breast CA, sciatica</td>
<td>Lorazepam, oxycodone, lansoprazole</td>
<td>Enlarged celiac node on CT scan</td>
<td>Reactive enlargement of lymph nodes</td>
<td>500 mg</td>
<td>60</td>
<td>Complete</td>
</tr>
<tr>
<td>5</td>
<td>89</td>
<td>F</td>
<td>Osteoporosis, glaucoma, Alzheimer’s disease</td>
<td>Aspirin</td>
<td>Pancreatic mass</td>
<td>Pancreatic adenocarcinoma</td>
<td>250 mg</td>
<td>30</td>
<td>Complete</td>
</tr>
<tr>
<td>6</td>
<td>74</td>
<td>F</td>
<td>Diabetes, CAD, CHF, h/o stroke, chronic bronchitis, osteoarthritis, depression, <em>hypothyroidism</em></td>
<td>Nitroglycerin, insulin glargine 20/10, synthroid, atorvastatin, atenolol, aspirin, venlafaxine</td>
<td>Pancreatic mass</td>
<td>Pancreatic adenocarcinoma</td>
<td>250 mg</td>
<td>60</td>
<td>Complete</td>
</tr>
<tr>
<td>7</td>
<td>87</td>
<td>M</td>
<td>Parkinsonism, HTN</td>
<td>Simvastatin, hydrochlorothiazide, finasteride, <em>carbidopa/levodopa</em>, filodipine, docusate</td>
<td>Esophageal mass on CT scan</td>
<td>Normal EUS of esophageal wall</td>
<td>500 mg</td>
<td>60</td>
<td>Complete</td>
</tr>
<tr>
<td>8</td>
<td>58</td>
<td>M</td>
<td>Chronic pancreatitis</td>
<td>Amlodipine, pantoprazole, <em>hydrocodone</em></td>
<td>Chronic pancreatitis</td>
<td>Chronic pancreatitis</td>
<td>500 mg</td>
<td>45</td>
<td>Complete</td>
</tr>
<tr>
<td>9</td>
<td>51</td>
<td>F</td>
<td><em>Hypothyroidism</em>, B-cell lymphoma</td>
<td>Esomeprazole</td>
<td>Enlarged periporal lymph nodes on CT scan</td>
<td>Benign reactive enlargement of lymph node</td>
<td>250 mg</td>
<td>30</td>
<td>Complete</td>
</tr>
<tr>
<td>10</td>
<td>66</td>
<td>M</td>
<td>CAD, HTN, <em>diabetes</em>, CHF and atrial fibrillation</td>
<td>Furosemide, tramadol, Pentoxifylline, digoxin, <em>atenolol</em>, amitryptilline, diltaizem, insulin, Acetaminophen, hydrocodone</td>
<td>Gastroesophageal junction nodule</td>
<td>Benign reactive nodule</td>
<td>250 mg</td>
<td>60</td>
<td>Complete</td>
</tr>
<tr>
<td>11</td>
<td>48</td>
<td>F</td>
<td>Alcoholic cirrhosis, s/p orthotopic liver transplant, <em>hypothyroidism</em></td>
<td>Synthroid, Lansoprazole valganciclovir, prednisone, insulin glargine, <em>dexametone</em>, propoxyphene, <em>klonopin</em>, tacrolimus</td>
<td>Peripancreatic mass lesion on CT</td>
<td>Normal EUS exam of pancreas and peripancreatic structures</td>
<td>500 mg</td>
<td>75</td>
<td>Partial</td>
</tr>
<tr>
<td>12</td>
<td>51</td>
<td>M</td>
<td>CAD, COPD</td>
<td>Carisoprodol, plavix, atorvastatin, oxycodone, gabapentin, niaspan</td>
<td>Abdominal pain and weight loss</td>
<td>Normal EGD and EUS exam of UGI tract</td>
<td>250 mg</td>
<td>60</td>
<td>Partial</td>
</tr>
<tr>
<td>13</td>
<td>51</td>
<td>M</td>
<td>Chronic pancreatitis, CHF, <em>Diabetes</em>, HTN</td>
<td>Clopidogrel, digoxin, aspirin, accupril, carvedilol, furosemide, atorvastatin, ezetimibe, <em>fluvastine</em>, cyclobenzaprine, hydrocodone</td>
<td>Abdominal pain</td>
<td>Celiac plexus block performed</td>
<td>60 mg</td>
<td>60</td>
<td>Partial</td>
</tr>
<tr>
<td>14</td>
<td>36</td>
<td>M</td>
<td>HTN, <em>Diabetes</em>, chronic pancreatitis, hypertriglyceridemia s/p appendicectomy</td>
<td>Fenofibrate, hydrocodone, oxycodone, gemfibrozil, pantoprazole, metformin, <em>pangestine</em></td>
<td>Pseudocyst</td>
<td>Large pseudocyst causing gastric outlet 250 mg obstruction</td>
<td>30</td>
<td>Failed</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>69</td>
<td>F</td>
<td>HTN, Hepatitis C s/p appendicectomy, s/p hernia repair</td>
<td>Pregabalin, aspirin, <em>Hydrochlorothiazide</em>, ferrous Sulfate, isobide, metoprolol, potassium naproxen</td>
<td>Pancreatic mass</td>
<td>Pancreatic adenocarcinoma with high grade duodenal obstruction</td>
<td>250 mg</td>
<td>60</td>
<td>Failed</td>
</tr>
</tbody>
</table>

IV-ER: Intravenous Erythromycin; EGD: Esophagogastroduodenoscopy; EUS: Endoscopic Ultrasonography; CT: Computed Tomography.
This study is limited by its retrospective design and lack of a control arm. However, a prospective study or a study with a control arm, are not practical in this clinical scenario. Another potential criticism is that the emptying of the gastric contents could just be a function of time and was not related to erythromycin. Due to lack of a control arm it is impossible to definitively exclude that possibility in our patients. However, most of the study patients had fasted more than 12 hours prior to procedure (even though 6 hours was recommended) and had multiple factors that are known to delay gastric emptying. It is possible but rather unlikely that they would empty their gastric contents spontaneously without the prokinetic effects of erythromycin in another 30 - 120 minutes after having failed to do so in >12 hours of pre-procedure fasting. The study has several strengths, the most important being the evaluation of the amount of retained gastric contents directly by endoscopy. Secondly, it provides direct evidence of efficacy and the rapidity of gastric emptying in this subset of patient in whom gastric emptying is so impaired that they are unable to empty their stomach despite adequate pre-procedure fasting. Lastly, it provides preliminary evidence showing that with use of erythromycin, retained gastric contents noted during UGIE procedures can be emptied within a reasonable time in a significant number of patients to allow for a repeat attempt at completion of the procedure on the same day.

In conclusion, in our retrospective case series of patients undergoing elective UGIE procedures, who were found to have a significant amount of residual food in the stomach during endoscopy, single dose of 250 - 500 mg IV erythromycin promoted emptying of the retained gastric contents rapidly except in patients with high grade mechanical obstruction. Trial of IV erythromycin may be worth a consideration for emptying retained gastric contents in patients undergoing UGIE procedures in an effort to avoid cancellation and be able to safely complete the procedure on the same day in selected patients.

REFERENCES


